References

  1. Jackson LA, Neuzil KM, Baggs J, et al. Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: a Vaccine Safety Datalink study. Pediatr 2006;118:2032-7.
  2. CDC. Rapid assessment of influenza vaccination coverage among HMO members--Northern California influenza seasons, 2001-02 through 2004-05. MMWR 2005;54:676-8.
  3. CDC. Estimated influenza vaccination coverage among adults and children--United States, September 1, 2004-January 31, 2005. MMWR 2005;54:304-7.
  4. Nowalk MP, Zimmerman RK, Lin CJ, et al. Parental perspectives on influenza immunization of children aged 6 to 23 months. Am J Prev Med 2005;29:210-4.
  5. Gnanasekaran SK, Finkelstein JA, Hohman K, et al. Parental perspectives on influenza vaccination among children with asthma. Public Health Rep 2006;121:181-8.
  6. Gaglani M, Riggs M, Kamenicky C, et al. A computerized reminder strategy is effective for annual influenza immunization of children with asthma or reactive airway disease. Pediatr Infect Dis J 2001; 20:1155-60.
  7. National Foundation for Infectious Diseases. Call to action: influenza immunization among health-care workers, 2003. Bethesda, MD: National Foundation for Infectious Diseases; 2003. Available at http://www.nfid.org/publications/
    calltoaction.pdf    .
  8. Poland GA, Tosh P, Jacobson RM. Requiring influenza vaccination for health care workers: seven truths we must accept. Vaccine 2005; 23:2251-5.
  9. CDC. Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No.RR-2).
  10. Walker FJ, Singleton JA, Lu P, et al. Influenza vaccination of health-care workers in the United States, 1989-2002. Infect Control Hosp Epidemiol 2006;27:257-65.
  11. Lu P, Singleton J. Influenza vaccination of pregnant women: Behavioral Risk Factor Surveillance System (BRFSS), 1997-2001. Presented at the Annual Behavioral Risk Factor Surveillance System Conference, St. Louis, Missouri; February 10-13, 2003.
  12. Yeager DP, Toy EC, Baker B III. Influenza vaccination in pregnancy. Am J Perinatol 1999;16:283-6.
  13. Gonik B, Jones T, Contreras D, et al. The obstetrician-gynecologist's role in vaccine-preventable diseases and immunization. Obstet Gynecol 2000;96:81-4.
  14. Zimmerman RK, Raymund M, Janosky JE, et al. Sensitivity and specificity of patient self-report of influenza and pneumococcal polysaccharide vaccinations among elderly outpatients in diverse patient care strata. Vaccine 2003;21:1486-91.
  15. American Academy of Pediatrics: Committee on Infectious Diseases. Prevention of influenza: recommendations for influenza immunization of children, 2006-2007. Pediatrics 2007;119:846-51.
  16. O'Mara D, Fukuda K, Singleton JA. Influenza vaccine: ensuring timely and adequate supply. Infect Med 2003;20:548-54.
  17. CDC. Assessing adult vaccination status at age 50 years. MMWR 1995;44:561-3.
  18. Fedson DS. Adult immunization. Summary of the National Vaccine Advisory Committee Report. JAMA 1994;272:1133-7.
  19. Talbot TR, Bradley SF, Cosgrove SE, et al. SHEA Position Paper: Influenza vaccination of health-care workers and vaccine allocation for health care workers during vaccine shortages. Infection Control Hosp Epidemiology 2005;26:882-90.
  20. CDC. Interventions to increase influenza vaccination of health-care personnel--California and Minnesota. MMWR 2005;54:196-9.
  21. Joint Commission on the Accreditation of Health Care Organizations. Joint Commission establishes infection control standard to address influenza vaccines for staff. Terrace, IL: Joint Commission on the Accreditation of Health Care Organizations; 2006. Available at http://www.jointcommission.org/newsroom/
    newsreleases/nr_06_13_06.htm
  22. Infectious Diseases Society of America. Pandemic and seasonal influenza: principles for U.S. action. Arlington, VA: Infectious Diseases Society of America; 2007. Available at http://www.idsociety.org/Content/
    NavigationMenu/News_Room1/
    Pandemic_and_Seasonal_Influenza/
    IDSA_flufinalAPPROVED1.24.07.pdf.
  23. Stewart A, Cox M, Rosenbaum S. The epidemiology of U.S. immunization law: immunization requirements for staff and residents of long-term care facilities under state laws/regulations. Washington, DC: George Washington University; 2005. Available at http://www.gwumc.edu/sphhs/healthpolicy/
    immunization/EUSIL-LTC-report.pdf    .
  24. Lindley MC, Horlick GA, Shefer AM, et al. Assessing state immunization requirements for healthcare workers and patients. Am J Prev Med 2007;32:459-65.
  25. CDC. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR 2003:52 (No RR-10).
  26. Heinonen OP, Shapiro S, Monson RR, et al. Immunization during pregnancy against poliomyelitis and influenza in relation to childhood malignancy. Int J Epidemiol 1973;2:229-35
  27. Pool V, Iskander J. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol 2006;194:1200.
  28. Deinard AS, Ogburn P Jr. A/NJ/8/76 influenza vaccination program: effects on maternal health and pregnancy outcome. Am J Obstet Gynecol 1981;140:240-5.
  29. CDC. Recommended adult immunization schedule--United States, October 2006-September 2007. MMWR 2006;SS:Q1-4.
  30. Miller JM, Tam TW, Maloney S, et al. Cruise ships: high-risk passengers and the global spread of new influenza viruses. Clin Infect Dis 2000;31:433-8.
  31. Uyeki TM, Zane SB, Bodnar UR, et al. Large summertime influenza A outbreak among tourists in Alaska and the Yukon Territory. Clin Infect Dis 2003;36:1095-102.
  32. Mutsch M, Tavernini M, Marx A, et al. Influenza virus infection in travelers to tropical and subtropical countries. Clin Infect Dis 2005;40:1282-7.
  33. Nichol KL, D'Heilly S, Ehlinger E. Colds and influenza-like illness in university students: impact on health, academic and work performance, and health care use. Clin Infect Dis 2005;40:1263-70.
  34. Awofeso N, Fennell M, Waliuzzaman Z, et al. Influenza outbreak in a correctional facility. Aust N Z J Public Health 2001;25:443-6.
  35. CDC. Vaccine-preventable diseases: improving vaccination coverage in children, adolescents, and adults: a report on recommendations from the Task Force on Community Preventive Services. MMWR 1999;48(No. RR-8).
  36. CDC. Use of standing orders programs to increase adult vaccination rates. MMWR 2000;49(No. RR-1):15-26.
  37. Gross PA, Russo C, Dran S, et al. Time to earliest peak serum antibody response to influenza vaccine in the elderly. Clin Diagn Lab Immunol 1997;4:491-2.
  38. Brokstad KA, Cox RJ, Olofsson J, et al. Parenteral influenza vaccination induces a rapid systemic and local immune response. J Infect Dis 1995;171:198-203.
  39. Lawson F, Baker V, Au D, et al. Standing orders for influenza vaccination increased vaccination rates in inpatient settings compared with community rates. J Gerontol A Biol Sci Med Sci 2000;55:M522-6.
  40. Centers for Medicare and Medicaid Services. Medicare and Medicaid Programs. Condition of participation: immunization standard for long term care facilities. Final rule. Federal Register 2005:70:194; 58834-52.
  41. Centers for Medicare and Medicaid Services. Medicare and Medicaid programs; conditions of participation: immunization standards for hospitals, long-term care facilities, and home health agencies. Final rule with comment period. Federal Register 2002;67:61808-14.
  42. Centers for Medicare and Medicaid Services. 2006-2007 Influenza (flu) season resources for health care professionals. Available at http://www.cms.hhs.gov/MLNMattersArticles/
    downloads/SE0667.pdf.
  43. Centers for Medicare and Medicaid Services. Emergency update to the 2007 Medicare Physician Fee Schedule Database (MPFSDB). Available at http://www.cms.hhs.gov/MLNMattersArticles/
    downloads/MM5459.pdf.
  44. Stefanacci RG. Creating artificial barriers to vaccination. J Am Med Dir Assoc 2005;6:357-8.
  45. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006 24: 1159-69.
  46. Simonsen L, Reichert TA, Viboud C, et al. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 2005;165:265-72.
  47. Jackson LA, Nelson JC, Benson P, et al. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol, 2006;35:345-52.
  48. Nichol KL, Nordin J, Mullooly J. Influence of clinical outcome and outcome period definitions on estimates of absolute clinical and economic benefits of influenza vaccination in community dwelling elderly persons. Vaccine 2006;24:1562-8.
  49. Weycker D, Edelsberg J, Halloran ME, et al. Population-wide benefits of routine vaccination of children against influenza. Vaccine 2005;23:1284-93.
  50. Longini IM, Halloran ME. Strategy for distribution of influenza vaccine to high-risk groups and children. Am J Epidemiol 2005;161:303-6.
  51. Jordan R, Connock M, Albon E, et al. Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence. Vaccine 2006;24:1047-62.
  52. Schwartz B, Hinman A, Abramson J, et al. Universal influenza vaccination in the United States: are we ready? Report of a meeting. J Infect Dis 2006;194(Suppl 2):S147-54.
  53. Abramson JS, Neuzil KM, Tamblyn SE. Annual universal influenza vaccination: ready or not? Clin Infect Dis 2006;42:132-5.
  54. Glezen WP. Herd protection against influenza. J Clin Virol 2006;37:237-43.
  55. Helms CM, Guerra FA, Klein JO, et al. Strengthening the nation's influenza vaccination system: A National Vaccine Advisory Committee assessment. Am J Prev Med 2005;29:221-226.
  56. Kandun IN, Wibisono H, Sedyaningsih ER, et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med 2006;355: 2186-94.
  57. Oner AF, Bay A, Arslan S, et al. Avian influenza A (H5N1) infection in eastern Turkey in 2006. N Engl J Med 2006;355:2174-7.
  58. Areechokchai D, Jiraphongsa C, Laosiritaworn Y, Hanshaoworakul W, Reilly MO. Investigation of avian influenza (H5N1) outbreak in humans--Thailand, 2004. MMWR 2006;55(Suppl):S3-6.
  59. Dinh PN, Long HT, Tien NTK, et al. Risk factors for human infection with avian influenza A H5N1, Vietnam, 2004. Emerg Infect Dis 2006;12:1841-7.
  60. Gilsdorf A, Boxall N, Gasimov V, et al. Ganter B. Two clusters of human infection with influenza A/H5N1 virus in the Republic of Azerbaijan, February-March 2006. Euro Surveill 2006;11:122-6.
  61. World Health Organization. Update: WHO-confirmed human cases of avian influenza A(H5N1) infection, 25 November 2003-24 November 2006. Wkly Epidemiol Rec 2007;82:41-8.
  62. Monto AS. The threat of an avian influenza pandemic. N Engl J Med 2005;352:323-5.
  63. Maines TR, Chen LM, Matsuoka Y, et al. Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl Acad Sci USA 2006;103:12121-6.
  64. CDC. Interim guidance for protection of persons involved in U.S. avian influenza outbreak disease control and eradication activities. Atlanta, GA: US Department of Health and Human Services, CDC; 2006. Available at http://www.cdc.gov/flu/avian/
    professional/protect-guid.htm    .
  65. Occupational Safety and Health Administration. OSHA guidance update on protecting employees from avian flu (avian influenza) viruses. Washington, DC: US Department of Labor, Occupational Safety and Health Administration; 2006. Available at http://www.osha.gov/OshDoc/
    data_AvianFlu/
    avian_flu_guidance_english.pdf    .
  66. Council of State and Territorial Epidemiologists. Council of State and Territorial Epidemiologists interim position statement. Atlanta, GA: Council of State and Territorial Epidemiologists; 2007. Available at http://www.cste.org/PS/2007ps/
    ID/07-ID-01.pdf    .
  67. CDC. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents-United States, 2005-06 influenza season. MMWR 2006;55:44-6.
  68. Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006;295:891-4
  69. Saito R, Li D, Suzuki H. Amantadine-resistant influenza A (H3N2) virus in Japan, 2005-2006. N Engl J Med 2007;356:312-3.
  70. Public Health Agency of Canada. Interim recommendation for use of amantadine for influenza. Ottowa, Canada: Public Health Agency of Canada; 2006. Available at http://www.phac-aspc.gc.ca/media/advisories_avis/2006/
    statement060115.html.
  71. CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005;54(No. RR-8).
  72. Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. Pediatr Infect Dis J 2003;22:164-77.
  73. Schmid ML, Kudesia G, Wake S, et al. Prospective comparative study of culture specimens and methods in diagnosing influenza in adults. BMJ 1998;316:275.
  74. Ali T, Scott N, Kallas W, et al. Detection of influenza antigen with rapid antibody-based tests after intranasal influenza vaccination (FluMist). Clin Infect Dis 2004;38:760-2.
  75. Anonymous. Rapid diagnostic tests for influenza. Med Lett Drugs Ther 1999;41:121-2.
  76. Storch GA. Rapid diagnostic tests for influenza. Curr Opin Pediatr 2003;15:77-84.
  77. Grijalva CG, Poehling KA, Edwards KM, et al. Accuracy and interpretation of rapid influenza tests in children. Pediatrics. 2007;119:e6-11.
  78. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005;366:1175-81.
  79. Belshe RB, Smith MH, Hall CB, et al. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol 1988;62:1508-12.
  80. Hay AJ, Zambon MC, Wolstenholme AJ, et al. Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother 1986;18(suppl B):19-29.
  81. Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987;80:275-82.
  82. Saito R, Oshitani H, Masuda H, et al. Detection of amantadine-resistant influenza A virus strains in nursing homes by PCR-restriction fragment length polymorphism analysis with nasopharyngeal swabs. J Clin Microbiol 2002;40:84-8.
  83. Hayden FG, Sperber SJ, Belshe RB, et al. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 1991;35:1741-7.
  84. Houck P, Hemphill M, LaCroix S, et al. Amantadine-resistant influenza A in nursing homes. Identification of a resistant virus prior to drug use. Arch Intern Med 1995;155:533-7.
  85. Hayden FG, Belshe RB, Clover RD, et al. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989;321:1696-702.
  86. Mast EE, Harmon MW, Gravenstein S, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 1991;134: 988-97.
  87. Gubareva LV, Robinson MJ, Bethell RC, et al. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997;71:3385-90.
  88. Colacino JM, Laver WG, Air GM. Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture. J Infect Dis 1997;176(Suppl 1):S66-8.
  89. Gubareva LV, Bethell R, Hart GJ, et al. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 1996;70:1818-27.
  90. Blick TJ, Tiong T, Sahasrabudhe A, et al. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 1995;214:475-84.
  91. McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, et al. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother 1996;40:40-6.
  92. Staschke KA, Colacino JM, Baxter AJ, et al. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 1995;214:642-6.
  93. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, et al. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 1998;72:2456-62.
  94. Tai CY, Escarpe PA, Sidwell RW, et al. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998;42:3234-41.
  95. Hay AJ, Wolstenholme AJ, Skehel JJ, et al. The molecular basis of the specific anti-influenza action of amantadine. Embo J 1985;4:3021-4.
  96. Appleyard G. Amantadine-resistance as a genetic marker for influenza viruses. J Gen Virol 1977;36:249-55.
  97. Roche Laboratories, Inc. Tamiflu (oseltamivir phosphate) capsules and oral suspension [Package insert]. Nutley, NJ: Roche Laboratories, Inc.; 2005.
  98. Barnett JM, Cadman A, Gor D, et al. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother 2000;44:78-87.
  99. Gubareva LV, Matrosovich MN, Brenner MK, et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998;178:1257-62.
  100. Gubareva LV, Kaiser L, Matrosovich MN, et al. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001;183:523-31.

Back